Portfolio Lab

Arrowhead Pharmaceuticals, Inc.

  • Stock
  • Ticker ARWR
  • ISIN US04280A1007
  • Nasdaq

Health care · Pharmaceuticals · USA

$41.37 −5.22%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Arrowhead Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ARWRGlobal equities (VT)

$10,000 grew to $95,103. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −89.0% in 04/2025, measured from the peak in 02/2021. The old peak has not been reached again yet.

1-year return
+8.6%
5-year return p.a.
−10.3%
10-year return p.a.
+25.3%
Volatility p.a.
76.2%
Largest decline
−89.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue2.554328256264747538
Operating income-161381-1664441-141-170-437
EBITDA-157387-1605047-135-164-430
Net income-173370-175-2431-133-194-428
Earnings per share-1.392.75-1.26-0.180.22-0.93-1.36-3.01
Balance sheet
Total assets1,0141,5731,3811,3851,6042,2682,1121,738
Liabilities9588898618821,0411,6691,6461,688
Equity5368352246656861446650
Cash541861302272021895563
Cash flow
Operating cash flow-146460-155201384-177-192
Capital expenditure-7.5-5.3-2.4-7.5-2.1-2.6-3.9-3.4
Free cash flow-154455-157131182-181-196

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +410.7%, weakest 2022 at −38.8%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
12 Nov 2026−$3.01
4 Aug 2026−$1.36
7 May 2026−$0.93
5 Feb 2026$0.22
25 Nov 2025−$0.18
7 Aug 2025−$1.26
12 May 2025$2.75
10 Feb 2025−$1.39
26 Nov 2024−$1.37
8 Aug 2024−$1.38
9 May 2024−$1.02
6 Feb 2024−$1.24

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€5.3bn
Market cap in trading currency
$5.85bn
Enterprise value
$4.66bn
P/E
–
P/S
12.97
P/B
116.24
EV/Sales
10.33
EV/EBITDA
–
Earnings yield
–
FCF yield
-4.9%

Results (last four quarters)

Revenue
$451m
Gross profit
–
EBITDA
−$682m
Net income
−$724m
Earnings per share
−$5.11
Revenue per share
$3.19
Revenue growth
−85.3%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-156.9%
Net margin
-160.6%
Return on equity
-280.5%
Return on assets
-41.7%

Balance sheet and cash flow

Cash
$1.19bn
Cash per share
$8.44
Financial debt
–
Debt/equity %
–
Current ratio
4.14
Book value per share
$0.36
Operating cash flow
−$272m
Free cash flow
−$284m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
141m
Volume
3.91m
Avg. volume 3 months
1.95m
Relative volume
1.9

Price and technicals

Price
$41.37
1 day
−5.2%
52-week high
$89.59
52-week low
$38.09
Distance to 52-week high
−53.8%
Distance to 52-week low
+8.6%
Distance to 50-day line
−30.2%
Distance to 200-day line
−41.3%
RSI (14)
21
Volatility 1M
72.3%

Performance

1 week
−13.4%
1 month
−29.1%
3 months
−52.3%
6 months
−44.8%
YTD
−37.7%
1 year
+6.2%

Dates

Fiscal year end
30 Sep 2026
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ARWR performed since 11/2016?

$10,000 grew to $95,103 by 20 Nov 2026, which is +25.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ARWR?

Volatility was 76.2% per year, measured on monthly returns. The largest decline from a peak was −89.0%, with the low in 04/2025.

How does ARWR compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ARWR returned +25.3% at 76.2%. The correlation of monthly returns was 0.29; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Arrowhead Pharmaceuticals, Inc. (ARWR): Return and risk